Greenwich Lifesciences Stock Performance

GLSI Stock  USD 26.85  1.12  4.35%   
Greenwich Lifesciences holds a performance score of 21 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 2.46, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Greenwich Lifesciences will likely underperform. Use Greenwich Lifesciences value at risk, and the relationship between the jensen alpha and skewness , to analyze future returns on Greenwich Lifesciences.

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Greenwich Lifesciences are ranked lower than 21 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Greenwich Lifesciences demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more

Greenwich Lifesciences Relative Risk vs. Return Landscape

If you would invest  823.00  in Greenwich Lifesciences on November 16, 2025 and sell it today you would earn a total of  1,862  from holding Greenwich Lifesciences or generate 226.25% return on investment over 90 days. Greenwich Lifesciences is currently generating 2.3154% in daily expected returns and assumes 8.6666% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of stocks are less volatile than Greenwich, and 54% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Greenwich Lifesciences is expected to generate 11.25 times more return on investment than the market. However, the company is 11.25 times more volatile than its market benchmark. It trades about 0.27 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Greenwich Lifesciences Target Price Odds to finish over Current Price

The tendency of Greenwich Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 26.85 90 days 26.85 
about 17.83
Based on a normal probability distribution, the odds of Greenwich Lifesciences to move above the current price in 90 days from now is about 17.83 (This Greenwich Lifesciences probability density function shows the probability of Greenwich Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.46 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Greenwich Lifesciences will likely underperform. In addition to that Greenwich Lifesciences has an alpha of 2.1577, implying that it can generate a 2.16 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Greenwich Lifesciences Price Density   
       Price  

Predictive Modules for Greenwich Lifesciences

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Greenwich Lifesciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Greenwich Lifesciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
15.9124.5833.25
Details
Intrinsic
Valuation
LowRealHigh
22.4331.1039.77
Details

Greenwich Lifesciences Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Greenwich Lifesciences is not an exception. The market had few large corrections towards the Greenwich Lifesciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Greenwich Lifesciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Greenwich Lifesciences within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
2.16
β
Beta against Dow Jones2.46
σ
Overall volatility
8.59
Ir
Information ratio 0.26

Greenwich Lifesciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Greenwich Lifesciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Greenwich Lifesciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Greenwich Lifesciences is way too risky over 90 days horizon
Greenwich Lifesciences appears to be risky and price may revert if volatility continues
Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0.
Greenwich Lifesciences currently holds about 15.64 M in cash with (7.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures
Roughly 51.0% of the company shares are held by company insiders

Greenwich Lifesciences Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Greenwich Stock often depends not only on the future outlook of the current and potential Greenwich Lifesciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Greenwich Lifesciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding13 M
Cash And Short Term Investments4.1 M

Greenwich Lifesciences Fundamentals Growth

Greenwich Stock prices reflect investors' perceptions of the future prospects and financial health of Greenwich Lifesciences, and Greenwich Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Greenwich Stock performance.

About Greenwich Lifesciences Performance

By evaluating Greenwich Lifesciences' fundamental ratios, stakeholders can gain valuable insights into Greenwich Lifesciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Greenwich Lifesciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Greenwich Lifesciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Things to note about Greenwich Lifesciences performance evaluation

Checking the ongoing alerts about Greenwich Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Greenwich Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Greenwich Lifesciences is way too risky over 90 days horizon
Greenwich Lifesciences appears to be risky and price may revert if volatility continues
Net Loss for the year was (15.79 M) with profit before overhead, payroll, taxes, and interest of 0.
Greenwich Lifesciences currently holds about 15.64 M in cash with (7.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures
Roughly 51.0% of the company shares are held by company insiders
Evaluating Greenwich Lifesciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Greenwich Lifesciences' stock performance include:
  • Analyzing Greenwich Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Greenwich Lifesciences' stock is overvalued or undervalued compared to its peers.
  • Examining Greenwich Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Greenwich Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Greenwich Lifesciences' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Greenwich Lifesciences' stock. These opinions can provide insight into Greenwich Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Greenwich Lifesciences' stock performance is not an exact science, and many factors can impact Greenwich Lifesciences' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences' price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account